Venrock Healthcare Capital Partners III, L.P., 10% Owner at KalVista Pharmaceuticals, Inc. (KALV), bought 204,841 shares at $9.29 ($1.9M) on 2025-02-07, disclosed to the SEC on 2025-02-11.
Open-market purchase of $1.9M KALV by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.29 | 73,649 | $684K | 36.1% |
| 2 | $9.29 | 73,649 | $684K | 36.1% |
| 3 | $9.14 | 4,137 | $38K | 2.0% |
| 4 | $9.18 | 26,703 | $245K | 12.9% |
| 5 | $9.18 | 26,703 | $245K | 12.9% |
| Total | $9.26 avg | 204,841 |
| $1.9M |
| 100% |
| Filing → |
| KALV | BUY | 2024-01-29 | $1.4M | — | Filing → |
| KALV | BUY | 2024-01-10 | $2.8M | — | Filing → |
| UMRX | BUY | 2020-08-18 | $1.4M | — | Filing → |